ImmunoPrecise Antibodies Ltd. (IPA) News
Filter IPA News Items
IPA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IPA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest IPA News From Around the Web
Below are the latest news stories about IMMUNOPRECISE ANTIBODIES LTD that investors may wish to consider to help them evaluate IPA as an investment opportunity.
ImmunoPrecise Antibodies announces resignation of CFOImmunoPrecise Antibodies (IPA) announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time. IPA has initiated a CFO succession process and will provide updates as appropriate. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> |
IPA Announces Resignation of Chief Financial OfficerAUSTIN, Texas, January 01, 2025--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time. |
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share PurchasesVICTORIA, British Columbia, December 23, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce significant insider activity, with key members of its executive team and subsidiary co-founders demonstrating confidence in the Company’s strategic direction and long-term potential through substantial share purchases. |
IPA to Present at The Microcap Conference 2025VICTORIA, BC / ACCESSWIRE / December 19, 2024 / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced is pleased to announce its participation in The ... |
ImmunoPrecise Antibodies Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagImmunoPrecise Antibodies ( NASDAQ:IPA ) Second Quarter 2025 Results Key Financial Results Revenue: CA$6.13m (flat on 2Q... |
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025VICTORIA, British Columbia, December 10, 2024--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the second quarter ("Q2") of its 2025 fiscal year ("FY25"), which ended October 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted. |
IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceVICTORIA, British Columbia, December 04, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced it will be presenting at The Benchmark Company’s 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024, at the New York Athletic Club in New York City. |
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024VICTORIA, British Columbia, December 03, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2025, on Tuesday, December 10, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will h |
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 /DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a ... |
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer TherapiesVICTORIA, British Columbia, November 13, 2024--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to announce a significant breakthrough in its primary cancer research initiatives. This accomplishment not only highlights IPA’s cutting-edge discovery and AI capabilities, but it also strategically places the company in the rapidly growing market for these cancer-combating antibodies, which is projected to reach $20.7 billion by |